AbbVie (ABBV) Non Operating Income (2012 - 2026)
AbbVie (ABBV) reported Non Operating Income of -$2.3 billion for Q1 2026, down 59.58% year-over-year from -$5.7 billion in Q1 2025, and down 90.58% on a QoQ basis from -$1.2 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Non Operating Income data on file, last reported at -$2.3 billion in Q1 2026.
- Quarterly Non Operating Income fell 59.58% year-over-year to -$2.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.7 billion (down 62.43% YoY) and the FY2025 annual result came in at -$5.8 billion, down 78.8% from the prior year.
- Non Operating Income slipped to -$2.3 billion in Q1 2026 per ABBV's latest filing, from -$1.2 billion in the prior quarter.
- Across five years, Non Operating Income topped out at $776.0 million in Q1 2022 and bottomed at -$2.6 billion in Q2 2025.
- The 5-year median for Non Operating Income is -$1.3 billion (2024), against an average of -$1.1 billion.
- The widest annual swing landed in 2022, when Non Operating Income jumped 1671.43%; it then tumbled 1320.0% in 2024.
- Tracing ABBV's Non Operating Income over 5 years: stood at -$2.0 billion in 2022, then climbed by 23.01% to -$1.6 billion in 2023, then jumped by 90.36% to -$150.0 million in 2024, then tumbled by 706.67% to -$1.2 billion in 2025, then tumbled by 90.58% to -$2.3 billion in 2026.
- Per Business Quant, the three latest ABBV Non Operating Income figures stand at -$2.3 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$503.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.31 Bn |
| Dec 31, 2025 | -1.21 Bn |
| Sep 30, 2025 | -503.00 Mn |
| Jun 30, 2025 | -2.64 Bn |
| Mar 31, 2025 | -1.45 Bn |
| Dec 31, 2024 | -150.00 Mn |
| Sep 30, 2024 | -1.16 Bn |
| Jun 30, 2024 | -1.35 Bn |
| Mar 31, 2024 | -586.00 Mn |
| Dec 31, 2023 | -1.56 Bn |
| Sep 30, 2023 | 95.00 Mn |
| Jun 30, 2023 | -1.41 Bn |
| Mar 31, 2023 | -1.80 Bn |
| Dec 31, 2022 | -2.02 Bn |
| Sep 30, 2022 | 330.00 Mn |
| Jun 30, 2022 | -1.53 Bn |
| Mar 31, 2022 | 776.00 Mn |
| Dec 31, 2021 | -216.00 Mn |
| Sep 30, 2021 | -21.00 Mn |
| Jun 30, 2021 | -2.66 Bn |
| Mar 31, 2021 | 395.00 Mn |
| Dec 31, 2020 | -4.63 Bn |
| Sep 30, 2020 | -115.00 Mn |
| Jun 30, 2020 | -802.00 Mn |
| Mar 31, 2020 | -72.00 Mn |
| Dec 31, 2019 | -416.00 Mn |
| Sep 30, 2019 | -177.00 Mn |
| Jun 30, 2019 | -2.28 Bn |
| Mar 31, 2019 | -135.00 Mn |
| Dec 31, 2018 | -518.00 Mn |
| Jun 30, 2018 | 500.00 Mn |
| Mar 31, 2018 | 153.00 Mn |
| Dec 31, 2017 | -17.00 Mn |
| Mar 31, 2017 | -61.00 Mn |
| Dec 31, 2016 | -36.00 Mn |
| Sep 30, 2016 | -101.00 Mn |
| Jun 30, 2016 | -51.00 Mn |
| Dec 31, 2015 | 12.00 Mn |
| Sep 30, 2015 | -28.00 Mn |
| Jun 30, 2015 | 4.00 Mn |
| Mar 31, 2015 | -1.00 Mn |
| Dec 31, 2014 | 726.00 Mn |
| Sep 30, 2014 | 29.00 Mn |
| Jun 30, 2014 | -8.00 Mn |
| Mar 31, 2014 | 3.00 Mn |
| Dec 31, 2013 | -13.00 Mn |
| Sep 30, 2013 | -5.00 Mn |
| Jun 30, 2013 | 4.00 Mn |
| Mar 31, 2013 | 15.00 Mn |
| Dec 31, 2012 | -30.00 Mn |
| Sep 30, 2012 | 13.00 Mn |
| Jun 30, 2012 | -11.00 Mn |
| Mar 31, 2012 | 37.00 Mn |